VIVACELLE BIO INC

Shreveport, LA · Founded 2013 · Biotech · Private

Cell therapy platform for sepsis treatment using engineered immune cells

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · vivacellebio.com

Sector: Biotech
Headquarters: Shreveport, LA
Founded: 2013
Latest Form D: $100K, Aug 2016
Total capital: $1.1M

Federal grants: $783K; 3 awards · 2021–2024; Rank in peer group#212 of 392
Private capital raised: $325K; 2 Form D · last Aug 2016; 122 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 4; 14 pending · first 2016; Rank in peer group#35 of 392

Capital timeline

Latest events

Aug 2024Federal grantHealth and Human S · Phase I · Development of VBI-1 as a novel treatment protocol for outpatient cardiac arrest$280K
Sep 2021Federal grantHealth and Human S · Phase I · Nitric Oxide redistribution by a phospholipid nanoparticle colloid to treat septic shock.$252K
Sep 2021Federal grantHealth and Human S · Phase I · Nitric Oxide redistribution by a phospholipid nanoparticle colloid to treat septic shock.$252K
Aug 2016Private capital raisedForm D · SEC · 2nd filing$100K
Feb 2014Private capital raisedForm D · SEC · 1st filing$225K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 392 peers

Line = median

Biotech · Molecule

Federal grantsBelow median
Granted patents#35 · top 9%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Cuthbert SimpkinsResearcherExecutive Officer, DirectorLinked by $252K in grants as PI
Diane SimpkinsExecutive Officer, DirectorNamed in SEC Form D filings
Edward NicholsExecutive OfficerNamed in SEC Form D filings
Harven DeShieldExecutive Officer, DirectorNamed in SEC Form D filings
Krishna TalluriExecutive OfficerNamed in SEC Form D filings
Paul BurtonExecutive Officer, DirectorNamed in SEC Form D filings

Show all 8 people

Ron DamperDirectorNamed in SEC Form D filings
Stephen KeithDirectorNamed in SEC Form D filings

What it has protected

USPTO · 4 granted of 18

Sep 26, 2024PendingCompositions And Methods For Treating Or Preventing Multiple Organ Dysfunction SyndromeUSPTOApplication 18736688
Jul 16, 2024GrantedCompositions And Methods For Treating Or Preventing Multiple Organ Dysfunction SyndromeUSPTOUS 12,036,321
Jul 21, 2020GrantedCompositions And Methods For Reducing Reperfusion InjuryUSPTOUS 10,716,756

Show all 18 patent records

Compositions And Methods For Treating Or Preventing Multiple Organ Dysfunction SyndromeSep 26, 2024 · Application 18736688Pending
Compositions And Methods For Treating Or Preventing Multiple Organ Dysfunction SyndromeJul 16, 2024 · US 12,036,321Granted
Compositions And Methods For Reducing Reperfusion InjuryJul 21, 2020 · US 10,716,756Granted
Compositions And Methods For Treating Conditions Related To Lack Of Blood Supply, Shock And Neuronal InjuriesJan 17, 2019 · Application 15759096Pending
Stable Micelle And/or Liposome Compositions And Uses ThereofOct 12, 2017 · Application 15511996Pending
Methods And Compositions For Treating Conditions Related To Lack Of Blood Supply, Shock And Neuronal InjuriesApr 18, 2017 · US 9,622,968Granted
Methods And Compositions For Treating Conditions Related To Lack Of Blood Supply, Shock And Neuronal InjuriesSep 13, 2016 · US 9,439,855Granted
Compositions And Methods For Reducing Reperfusion InjuryApplication 62352285Pending
Stable Micelle And/or Liposome Compositions And Uses ThereofApplication PCTUS2015050520Pending
Methods And Compositions For Treating Conditions Related To Lack Of Blood Supply, Shock And Neuronal InjuriesApplication 62218200Pending
Compositions And Methods For Treating HyperprocalcitonemiaApplication 19146687Pending
Method And Compositions For Treating Conditions Related To Lack Of Blood Suppply, Shock And Neuronal InjuriesApplication PCTUS2013054356Pending
Compositions And Methods For Treating HyperprocalcitonemiaApplication PCTUS2024011961Pending
Compositions And Methods For Treating HyperprocalcitonemiaApplication 63482540Pending
Compositions And Methods For Treating Or Preventing Multiple Organ Dysfunction SyndromeApplication PCTUS2021070351Pending
Compositions And Methods For Treating Or Preventing Multiple Organ Dysfunction SyndromeApplication 63004769Pending
Compositions And Methods For Reducing Reperfusion InjuryApplication PCTUS2017037729Pending
Compositions And Methods For Treating Conditions Related To Lack Of Blood Supply, Shock And Neuronal InjuriesApplication PCTUS2016051654Pending

Atrin PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
PANTHERICS INCORPORATEDSimilar federal contract value in Biotech · null in contracts
MITOTHERAPEUTIX, LLCSimilar federal contract value in Biotech · null in contracts
FLAG THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
Inomagen Therapeutics, IncSimilar federal contract value in Biotech · null in contracts
NOBILIS THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.